XenoPort (NASDAQ: XNPT) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare XenoPort to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.
This table compares XenoPort and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares XenoPort and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|XenoPort Competitors||$8.31 billion||$1.11 billion||143.36|
XenoPort’s competitors have higher revenue and earnings than XenoPort. XenoPort is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for XenoPort and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceuticals” companies have a potential upside of 18.96%. Given XenoPort’s competitors higher probable upside, analysts plainly believe XenoPort has less favorable growth aspects than its competitors.
XenoPort competitors beat XenoPort on 7 of the 8 factors compared.
XenoPort Company Profile
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.
Receive News & Ratings for XenoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XenoPort and related companies with MarketBeat.com's FREE daily email newsletter.